Geode Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-807,517
| Closed | -$170K | – | 4824 |
|
|
2023
Q2 | $170K | Hold |
807,517
| – | – | ﹤0.01% | 4111 |
|
|
2023
Q1 | $129K | Hold |
807,517
| – | – | ﹤0.01% | 4243 |
|
|
2022
Q4 | $448K | Sell |
807,517
-62,058
| -7% | -$52.8K | ﹤0.01% | 3708 |
|
|
2022
Q3 | $1.03M | Hold |
869,575
| – | – | ﹤0.01% | 3366 |
|
|
2022
Q2 | $549K | Sell |
869,575
-562,049
| -39% | -$431K | ﹤0.01% | 3710 |
|
|
2022
Q1 | $1.63M | Sell |
1,431,624
-200,937
| -12% | -$240K | ﹤0.01% | 3364 |
|
|
2021
Q4 | $3.67M | Sell |
1,632,561
-101,471
| -6% | -$255K | ﹤0.01% | 3065 |
|
|
2021
Q3 | $5.93M | Buy |
1,734,032
+319,114
| +23% | +$984K | ﹤0.01% | 2805 |
|
|
2021
Q2 | $4.23M | Buy |
1,414,918
+726,749
| +106% | +$2.3M | ﹤0.01% | 3005 |
|
|
2021
Q1 | $2.22M | Buy |
688,169
+305,092
| +80% | +$1.02M | ﹤0.01% | 3211 |
|
|
2020
Q4 | $812K | Buy |
383,077
+11,217
| +3% | +$18.5K | ﹤0.01% | 3426 |
|
|
2020
Q3 | $435K | Hold |
371,860
| – | – | ﹤0.01% | 3468 |
|
|
2020
Q2 | $336K | Buy |
371,860
+8,243
| +2% | +$7.86K | ﹤0.01% | 3501 |
|
|
2020
Q1 | $304K | Hold |
363,617
| – | – | ﹤0.01% | 3425 |
|
|
2019
Q4 | $349K | Hold |
363,617
| – | – | ﹤0.01% | 3623 |
|
|
2019
Q3 | $374K | Hold |
363,617
| – | – | ﹤0.01% | 3571 |
|
|
2019
Q2 | $654K | Buy |
363,617
+9,570
| +3% | +$15.4K | ﹤0.01% | 3370 |
|
|
2019
Q1 | $665K | Hold |
354,047
| – | – | ﹤0.01% | 3318 |
|
|
2018
Q4 | $417K | Hold |
354,047
| – | – | ﹤0.01% | 3443 |
|
|
2018
Q3 | $959K | Buy |
354,047
+10,204
| +3% | +$21.1K | ﹤0.01% | 3239 |
|
|
2018
Q2 | $656K | Buy |
343,843
+18,276
| +6% | +$36.9K | ﹤0.01% | 3346 |
|
|
2018
Q1 | $683K | Hold |
325,567
| – | – | ﹤0.01% | 3289 |
|
|
2017
Q4 | $660K | Buy |
325,567
+59,064
| +22% | +$123K | ﹤0.01% | 3255 |
|
|
2017
Q3 | $354K | Sell |
266,503
-1,695
| -0.6% | -$2.1K | ﹤0.01% | 3472 |
|
|
2017
Q2 | $421K | Sell |
268,198
-77,168
| -22% | -$149K | ﹤0.01% | 3413 |
|
|
2017
Q1 | $1.11M | Buy |
345,366
+15,005
| +5% | +$36.9K | ﹤0.01% | 2968 |
|
|
2016
Q4 | $445K | Buy |
330,361
+10,951
| +3% | +$14.3K | ﹤0.01% | 3309 |
|
|
2016
Q3 | $498K | Buy |
319,410
+4,009
| +1% | +$6.16K | ﹤0.01% | 3250 |
|
|
2016
Q2 | $419K | Sell |
315,401
-21,534
| -6% | -$101K | ﹤0.01% | 3288 |
|
|
2016
Q1 | $1.77K | Buy |
336,935
+31,878
| +10% | +$195K | ﹤0.01% | 2543 |
|
|
2015
Q4 | $2.39M | Sell |
305,057
-59,621
| -16% | -$513K | ﹤0.01% | 2348 |
|
|
2015
Q3 | $3.08M | Buy |
364,678
+8,784
| +2% | +$81K | ﹤0.01% | 2153 |
|
|
2015
Q2 | $3.9M | Buy |
355,894
+31,923
| +10% | +$410K | ﹤0.01% | 2083 |
|
|
2015
Q1 | $4.53M | Sell |
323,971
-13,670
| -4% | -$209K | ﹤0.01% | 1916 |
|
|
2014
Q4 | $5.7M | Buy |
337,641
+100,147
| +42% | +$1.46M | ﹤0.01% | 1731 |
|
|
2014
Q3 | $3.19M | Buy |
237,494
+2,523
| +1% | +$30K | ﹤0.01% | 2059 |
|
|
2014
Q2 | $2.99M | Buy |
234,971
+8,812
| +4% | +$91.8K | ﹤0.01% | 2137 |
|
|
2014
Q1 | $2.69M | Buy |
226,159
+8,432
| +4% | +$113K | ﹤0.01% | 2165 |
|
|
2013
Q4 | $3.01M | Buy |
217,727
+20,631
| +10% | +$291K | ﹤0.01% | 2058 |
|
|
2013
Q3 | $3.44M | Sell |
197,096
-7,367
| -4% | -$141K | ﹤0.01% | 1829 |
|
|
2013
Q2 | $3.32M | Buy |
+204,463
| New | +$6.33M | ﹤0.01% | 1713 |
|
Other funds holding INFI
Geode Capital Management's INFI Position: Q3 2023 in Review
Geode Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 807,517 shares — an estimated $170K sold.
Geode Capital Management first reported a position in INFI in Q2 2013 and held it in 41 quarters. The position peaked at $5.93M in Q3 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- Geode Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Geode Capital Management sold 807,517 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $170K.
- Geode Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Geode Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $5.93M in Q3 2021.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.